chronic lymphocytic leukaemia
NICE recommends axunio’s Axhidrox cream for adults with severe hyperhydrosis
Excessive sweating affects 1-5% of the population and can have a substantial impact on quality of life
NICE recommends treatments for mantle cell lymphoma and chronic lymphocytic leukaemia
The treatments are for eligible adults in England and Wales
AstraZeneca’s Trixeo recommended by CHMP for approval in EU for asthma
Asthma affects over 360 million people worldwide, including over 40 million people in Europe
AstraZeneca agrees on $1.5bn deal with Dizal Pharmaceutical
The company will gain a novel oral treatment for lung cancer
NICE recommends Genmab’s Tivdak for recurrent or metastatic cervical cancer
It is estimated that 3,300 women are diagnosed with cervical cancer in the UK each year
AstraZeneca reports positive phase 3 data for tozorakimab in COPD
COPD affects nearly 400 million people globally and is the third leading cause of death worldwide
AstraZeneca’s Imfinzi approved in EU for early gastric and gastro-oesophageal cancers
This is the first and only perioperative immunotherapy approved to treat early gastric cancers
AstraZeneca’s Imfinzi regimen receives positive CHMP opinion for early gastric and gastroesophageal cancer
Gastric cancer is the fifth highest cause of cancer deaths worldwide, with almost a million people diagnosed annually
AstraZeneca and CSPC Pharmaceuticals enter collaboration on weight management therapies
Almost three billion people globally are thought to be either overweight or obese
AstraZeneca announces $15bn investment in Chinese manufacturing and R&D by 2030
The pharma company will be the first global biopharma with end-to-end cell therapy capabilities in China
Sanofi and Regeneron’s Dupixent receives positive NICE final draft guidance for COPD
Around 1.4 million people in the UK are diagnosed with COPD, with two million thought to be undiagnosed
AstraZeneca’s Saphnelo demonstrates positive results in systemic lupus erythematosus
Over 3.4 million people globally are affected by SLE, and it is one of the leading causes of death in young women in the US